
Saniona Investor Relations Material
Latest events

Status Update
Saniona

Q1 2025
28 May, 2025

Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Saniona
Access all reports
Saniona AB is a clinical-stage biopharmaceutical company based in Denmark, focused on the discovery and development of treatments for central nervous system, autoimmune, metabolic diseases, and pain management. The company specializes in modulating ion channels, a class of proteins critical in cellular signaling. Saniona has built a proprietary drug discovery platform that includes more than 20,000 ion channel-modulating molecules. The company is headquartered in Ballerup, Denmark, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
SANION
Country
🇸🇪 Sweden